ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC - Episode 3
Long-Term Data From CheckMate 9ER Investigating Nivolumab Plus Cabozantinib in Untreated Advanced RCC
Experts discuss the key findings from the final follow-up results of the CheckMate 9ER trial, evaluating nivolumab plus cabozantinib in advanced renal cell carcinoma (RCC) and share perspectives on the clinical implications of these updated data, along with insights from other studies of note, including LITESPARK-003 (belzutifan plus cabozantinib) and LITESPARK-024 (belzutifan plus palbociclib).
Video Player is loading.
Video content above is prompted by the following:
- The CheckMate 9ER trial established the efficacy of nivolumab plus cabozantinib in advanced RCC. Could you review the key findings from the final follow-up results and share your perspectives on the clinical implications of these updated data?
- Please feel free to highlight other studies of note:
- LITESPARK-003 (belzutifan plus cabozantinib)
- LITESPARK-024 (belzutifan plus palbociclib)
- Please feel free to highlight other studies of note:
Related Content:
